* TELA Bio Inc TELA.OQ TELA.O is expected to show a rise
in
quarterly revenue when it reports results on November 7 for the
period ending January 1 0001
* The Malvern Pennsylvania-based company is expected to
report a
25.2% increase in revenue to $18.852 million from $15.05 million
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for TELA Bio Inc is for a
loss
of 40 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for TELA Bio
Inc is
12.00, above its last closing price of $2.92.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.46 -0.47 -0.51 Missed -8.1
Jan. 1 2024 -0.51 -0.50 -0.23 Beat 54.1
Jan. 1 0001 -0.42 -0.43 -0.53 Missed -21.9
Jan. 1 0001 -0.49 -0.49 -0.45 Beat 8.5
Jan. -0.53 -0.53 -0.46 Beat 13.7
1 0001
Jan. 1 0001 -0.56 -0.56 -0.63 Missed -12.7
Dec. 31 2022 -0.51 -0.55 -0.52 Beat 4.8
Sep. 30 2022 -0.63 -0.63 -0.64 Missed -2.3
This summary was machine generated November 6 at 04:35 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)